NCT01664624: Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes |
|
|
| Completed | 1b | 40 | US | Roflumilast, Daxas, Daliresp, Alogliptin, Nesina, Exenatide, Byetta, Bydureon, Placebo to roflumilast, Placebo to alogliptin | AstraZeneca | Type 2 Diabetes | 11/12 | 11/12 | | |
